Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 991-1002

  Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

EGFR inhibition; Epidermal growth factor receptor (EGFR); Non small cell lung cancer (NSCLC)

Indexed keywords

AMINO ACIDS; CELLS; CHEMOTHERAPY; DRUG THERAPY; ENZYMES; GROWTH KINETICS; MONOCLONAL ANTIBODIES; PLATINUM; RADIOTHERAPY; SKIN; TUMORS;

CYTOTOXICITY; LUNG CANCER;

ONCOLOGY;

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINOTRANSFERASE; BIOLOGICAL MARKER; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ERYTHROMYCIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; LOPERAMIDE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TAMOXIFEN; TAXANE DERIVATIVE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ACNE; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DIARRHEA; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; ERYTHEMA; FATIGUE; FOLLICULITIS; GASTROINTESTINAL TOXICITY; GENERAL CONDITION IMPROVEMENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MOLECULE; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PUSTULE; QUALITY OF LIFE; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DEFECT; SKIN TOXICITY; TREATMENT FAILURE; VOMITING;

EID: 1242293090     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.099     Document Type: Conference Paper

References (55)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin. 50:2000;7-33.
2. Cancer facts and figures 2001. 2001;American Cancer Society, New York.
3. Johnson D.H. Treatment strategies for metastatic non-small-cell lung cancer. Clin Lung Cancer. 1:1999;34-41.
4. Roszkowski K., Pluzanska A., Krazakowski M., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 27:2000;145-157.
5. Ranson M., Davidson N., Nicolson M., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 92:2000;1074-1080.
6. Anderson H., Cottier B., Nicolson M., et al. Phase III study of gemcitabine (Gemzar) vs. best supportive care (BSC) in advance non-small-cell lung cancer (NSCLC) [Abstract]. Lung Cancer. 18:1997;9.
7. Effects of vinorelbine on quality of life and survival of elderly patients with advance non-small-cell lung cancer. J Natl Cancer Inst. 91:1999;66-72.
8. Sandler A., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patient with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 18:2000;122-130.
9. Wozniak A., Crowley J., Balcerzak S.P. Randomized trial comparing cisplatin with cisplatin-vinorelbine in the treatment of advanced non-small cell lung cancer A Southwest Oncology Group study . J Clin Oncol. 16:1998;2459-2465.
10. Kelly K, Crowley J, Bunn P, et al. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial [Abstract]. J Clin Oncol 2001;19:3210-3218.
11. Schiller J.H., Harrington D., Belani C., et al. A comparison of four chemotherapy regimens for advanced non-small cell lung cancer (NSCLC). N Engl J Med. 346:2002;92-98.
12. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol. 20:2001;308a.
13. Van Meerbeeck J.P., Smit E.F., Lianes P., et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol. 20:2001;308a.
14. Belani C., Barstis J., Perry M., et al. Phase II multicenter randomized trial of weekly paclitaxel (P) administered in combination with carboplatin (C) followed by maintenance P vs. observation for patients (pts) with advanced and metastatic non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol. 20:2001;323a.
15. Rodriguez J., Pawel J., Pluzanska A., et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol. 20:2001;314a.
16. Shepherd F., Giaccone G., Debruyne C., et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy An NIC-CTG and EORTC study . Proc Am Soc Clin Oncol. 20:2001;4a.
17. Smylie M., Mercier R., Aboulafia D., et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol. 20:2001;307a.
18. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 8:2001;3-9.
19. Fontanini G., Vignati S., Bigini D., et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metabolic involvement of the hilar and mediastinal lymph nodes in squamous subtypes. Eur J Cancer. 31A:1995;178-183.
20. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor receptor (EGFr) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients with advanced EGFr-expressing non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol. 20:2001;310a.
21. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 196:2000;550-565.
22. Baselga J., Averbuch S.D. ZD1839 (Iressa) as an anticancer agent. Drugs. 60:2000;33-42.
23. Barker A.J., Gibson K.H., Grundy W., et al. Studies leading to the identification of ZD1839 (Iressa) An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer . Bioorg Med Chem Lett. 11:2001;1911-1914.
24. Meric J.B., Faivre S., Monnerat C., et al. ZD1839 "Iressa" Bull Cancer. 87:2000;873-876.
25. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;4885-4892.
26. Baselga J., Herbst R., LoRusso P., et al. Continuous administration of AD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with five selected tumor types evidence of activity and good tolerability [Abstract] . Proc Am Soc Clin Oncol. 19:2000;177a.
27. Nagakawa K., Yamamoto N., Kudoh S., et al. A phase I intermittent dose-escalation trial of ZD 1839 (Iressa) in Japanese patients with solid malignant tumors [Abstract]. Proc Am Soc Clin Oncol. 19:2000;183a.
28. Herbst R.S., Khuri F.R., Fossella F.V., et al. ZD1839 (Iressa™) in non-small-cell lung cancer. Clin Lung Cancer. 3:2001;21-32.
29. Kris M.G., Herbst R., Rischin D., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 IRESSA A selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) [Abstract] . Lung Cancer. 29:(Suppl. 1):2000;71.
30. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer who failed platinum- and docetaxel- based regimens. Proc Am Soc Clin Oncol 2002;21:292a.
31. Natale RB, Skarin A, Maddox A-M, et al. Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD 1839 (Iressa) in IDEAL 2 [Abstract]. Proc Am Soc Clin Oncol 2002;21:292a.
32. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;21:2237-2246.
33. Douillard J-Y, Giaccone G, Horai T, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-lung cancer (NSCLC) treated with ZD 1839 (Iressa) (IDEAL 1) [Abstract]. Proc Am Soc Clin Oncol 2002;21:299a.
34. Ruckdeschel JC, Simon G, Antonia S, et al. ZD 1839 (Iressa) as a single agent for the treatment of metastatic non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 2002;21:318a.
35. Janne PA, Ostler PA, Lucca J, et al. ZD 1839 (Iressa) shows antitumor activity in patients with recurrent non-small-cell lung cancer treated on a compassionate use protocol [Abstract]. Proc Am Soc Clin Oncol 2002;21:319a.
36. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT-1). Ann Oncol. 13:(Suppl. 5):2002;2.
37. Johnson D.H., Herbst R., Giaccone G., et al. ZD 1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) Initial results from a phase III trial (INTACT-2) . Ann Oncol. 13:(Suppl. 5):2002;127.
38. Albain K.S., Green S.J., Ravdin P.M., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent Initial results from Intergroup Trial 0100(SWOG-8814) . Proc Am Clin Oncol. 21:2002;A143.
39. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 3:1997;2703-2707.
40. Herbst R.S., Kim E.S., Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Expert Opin Biol Ther. 1:2001;1-14.
41. Fan Z., Baselga J., Masui H., et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53:1993;4637-4642.
42. Prewett M., Rockwell P., Rose C., et al. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin. Int J Oncol. 9:1996;217-224.
43. Perrotte P., Matsumoto T., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 5:1999;257-265.
44. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radio-response by C225 anti-epidermal growth factor receptor antibody. Clin Cancer Res. 6:2000;701-708.
45. Baselga J., Pfister D., Cooper M.R., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 18:2000;904-914.
46. Hong W.K., Arquette M., Nabell L., et al. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin-containing chemotherapy [Abstract]. Proc Am Soc Clin Oncol. 20:2001;224a.
47. Kies M.S., Arquette M.A., Nabell L., et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin-containing chemotherapy [Abstract]. Proc Am Soc Clin Oncol. 21:2002;232a.
48. Burtness BA, Li Y, Flood W, et al. Phase III trial comparing cisplatin and placebo to cisplatin and anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic/recurrent head and neck cancer [Abstract]. Proc Am Soc Clin Oncol 2002.
49. Harari P.M., Huang S.M. Modulation of molecular targets to enhance radiation. Clin Cancer Res. 6:2000;323-325.
50. Bonner J, Robert F, Raisch K. The epidermal growth factor receptor (EGFR) as a therapeutic target in squamous cell malignancies. Clin Can Research 2000;6(Suppl.):4481S.
51. Kim E.S., Mauer A.M., Fossella F.V., et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol. 21:2002;293a.
52. Rinehart J.J., Wilding G., Willson J., et al. A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosinekinase inhibitor in patients with advanced solid tumors [Abstract]. Proc Am Soc Clin Oncol. 21:2002;11A.
53. Murren JR, Papadimitrakopoulou VA, Sizer KC, et al. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI 166, a novel tyrosine kinase inhibitor in patients with advanced cancers [Abstract]. Proc Am Soc Clin Oncol 2002;21:95a.
54. DeSimone P.A., Bence A.K., Anderson E.B., et al. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW 572016 in healthy volunteers [Abstract]. Proc Am Soc Clin Oncol. 21:2002;94A.
55. Adams V.R., Bence A.K., Anderson E.B., et al. A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW 572016 in healthy subjects [Abstract]. Proc Am Soc Clin Oncol. 21:2002;94A.